Agata Mostkowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agata Mostkowska has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Guy Rousseau
Centre de biomédecine, Hôpital du Sacré-Cœur de Montréal, 5400 boul. Gouin Ouest, Montréal, Québec, Canada H4J 1C5; Département de pharmacologie, Université de Montréal, C.P. 6128 Succursale Centre-ville, Montréal, Québec, Canada H3C 3J7
1 shared publication - Noel J. M. Raynal
Centre de recherche du CHU Sainte-Justine, Montreal, QC, Canada
1 shared publication
Latest Publications
- Open Access
- 12 March 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (5) , e23536
Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases
Rituximab, the first monoclonal antibody approved for the treatment of lymphoma, eventually became one of the most popular and versatile drugs ever in terms of clinical application and revenue. Since its patent expiration, and consequently, the loss of exclusivity of the original biologic, its repurposing as an off‐label drug has increased dramatically, propelled by the development and commercialization of its many biosimilars. Currently, rituximab is prescribed worldwide to treat a vast range of autoimmune diseases mediated by B cells. Here, we present a comprehensive overview of rituximab repurposing in 115 autoimmune diseases across 17 medical specialties, sourced from over 1530 publications. Our work highlights the extent of its off‐label use and clinical benefits, underlining the success of rituximab repurposing for both common and orphan immune‐related diseases. We discuss the scientific mechanism associated with its clinical efficacy and provide additional indications for which rituximab could be investigated. Our study presents rituximab as a flagship example of drug repurposing owing to its central role in targeting cluster of differentiate 20 positive (CD20) B cells in 115 autoimmune diseases.
- 12 March 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (5) , e23536
Open AccessRepurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases
Rituximab, the first monoclonal antibody approved for the treatment of lymphoma, eventually became one of the most popular and versatile drugs ever in terms of clinical application and revenue. Since its patent expiration, and consequently, the loss of exclusivity of the original biologic, its repurposing as an off‐label drug has increased dramatically, propelled by the development and commercialization of its many biosimilars. Currently, rituximab is prescribed worldwide to treat a vast range of autoimmune diseases mediated by B cells. Here, we present a comprehensive overview of rituximab repurposing in 115 autoimmune diseases across 17 medical specialties, sourced from over 1530 publications. Our work highlights the extent of its off‐label use and clinical benefits, underlining the success of rituximab repurposing for both common and orphan immune‐related diseases. We discuss the scientific mechanism associated with its clinical efficacy and provide additional indications for which rituximab could be investigated. Our study presents rituximab as a flagship example of drug repurposing owing to its central role in targeting cluster of differentiate 20 positive (CD20) B cells in 115 autoimmune diseases.